Joint Determinants of Bone Density and CVD Calcification
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00037414|
Recruitment Status : Completed
First Posted : May 17, 2002
Last Update Posted : August 23, 2016
|Condition or disease|
|Atherosclerosis Cardiovascular Diseases Heart Diseases Osteoporosis|
There is growing evidence of a link between osteoporosis and atherosclerosis. Recent studies document that bone mineral density (BMD) is inversely correlated with severity of aortic and coronary artery calcification, markers of atherosclerosis. Cardiovascular disease and osteoporosis have tremendous negative public health impacts on the nation. Besides increased mortality, these negative impacts include severely diminished quality of life and huge financial burdens. With an ever aging population, this situation will get even worse. As increasing numbers of individuals now live well into their 80s and 90s, there is a great deal of interest on what has become known as healthy aging.
The study is in response to a Request for Applications (RFA) entitled Bone Formation and Calcification in Cardiovascular Disease which was developed jointly with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to support research into the pathophysiology and molecular mechanisms of vascular calcification, and the possible links between vascular calcification, bone formation, and cardiovascular disease. The RFA was released in January, 2001.
The study evaluates the relationship between BMD and coronary artery and aortic calcification, measured by electron beam computed tomography, in 700 members of a large Amish pedigree already participating in the Amish Family Osteoporosis Study (AFOS). By focusing on families, the investigators hope to tease out the respective contributions of genetic and non-genetic factors to this clustering of traits. The AFOS was initiated in 1997 to identify genes influencing susceptibility to osteoporosis in families ascertained for fracture risk. Through NIH funding available to the AFOS parent study, the investigators will genotype 391 highly polymorphic short tandem repeat (STR) markers spaced at approximately 10 cM intervals and perform a genome-wide scan to detect quantitative trait loci (QTLs) associated with variation in bone marrow density and related traits. The Old Order Amish are ideal for the studies since they are a closed founder population who are relatively genetically homogeneous, have very large family sizes, and well-documented genealogies. The study uses the available measures of bone marrow density, related traits, and genotypes in the AFOS along with the newly collected measures of vascular calcification.
The specific goals are to determine if bone marrow density is correlated with coronary artery and aortic calcification (CAC) and, if so, to determine the contribution of common genes or shared environments to this association in families. The investigators will next assess genetic heritability and non-genetic contributions to variability in vascular calcification determinants of CAC in these families. They will assess the individual and joint contributions of lipid oxidation to bone marrow density and vascular calcification. Using the extensive genotyping that will be available, they will perform a genome wide scan of coronary artery and aortic calcification. These results will complement the similar analyses obtained on the bone-related phenotypes. Finally, they will determine if chromosomal regions linked to variation in bone marrow density are also linked to variation in vascular calcification or to another possible joint determinant such as CAC (or to lipid oxidation).
|Study Type :||Observational|
|Study Start Date :||September 2001|
|Actual Primary Completion Date :||July 2006|
|Actual Study Completion Date :||July 2006|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00037414
|OverallOfficial:||Braxton Mitchell||University of Maryland Baltimore Professional School|